Abstract
Abatacept (CTLA4Ig), a selective T-cell costimulation modulator, has been approved for the treatment of psoriatic arthritis patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs, but not for those with uncontrolled skin lesions, nor with axial involvement. In this review, we will try to interpret such a differential efficacy of abatacept on the psoriatic arthritis clinical domains, on the basis of its differential effectiveness on the diverse T-cell subsets at different sites. Clinical and biological profiles of abatacept possible responders will be provided.
| Lingua originale | Inglese |
|---|---|
| pagine (da-a) | N/A-N/A |
| Rivista | Immunotherapy |
| Numero di pubblicazione | N/A |
| DOI | |
| Stato di pubblicazione | Pubblicato - 2018 |
OSS delle Nazioni Unite
Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile
-
SDG 3 Salute e benessere
All Science Journal Classification (ASJC) codes
- Immunologia e Allergia
- Immunologia
- Oncologia
Keywords
- CD28
- CTLA-4
- CTLA4Ig
- T cells
- abatacept
- enthesitis
- obesity
- psoriasis
- psoriatic arthritis
- therapy
Fingerprint
Entra nei temi di ricerca di 'Abatacept in the treatment of psoriatic arthritis: biological and clinical profiles (of the responders).'. Insieme formano una fingerprint unica.Cita questo
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver